TB diagnostic based on antigens from M. tuberculosis
AssigneeStatens Serum Institut
InventorsPeter Andersen, Karin Weldingh, Christina Hansen, Walter Florio, Li Mei Okkels, Rikke Skjot, Peter Rasmussen
Life of this patent
Estimating the term…
Abstract
The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as diagnostic reagents containing the polypeptides.
Claims20
A pharmaceutical composition comprising a combination of two or more substantially pure polypeptides, of which one or more comprises at least one amino acid sequence selected from the group consisting of:
- a) Rv3354 (SEQ ID NO. 148);
- b) an immunogenic portion of the sequence in (a);
- and
- c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic.
A diagnostic tool comprising a combination of two or more substantially pure polypeptides, of which at least one comprises at least one amino acid sequence selected from the group sonsisting of:
- (a) Rv3354 (SEQ ID NO. 148);
- (b) an immunogenic portion of the sequence in (a);
- and
- (c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic
A substantially pure polypeptide, which comprises an amino acid sequence selected from the group consisting of:
- (a) Rv3354 (SEQ ID NO. 148);
- (b) an immunogenic portion of the sequence in (a);
- and
- (c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic
A serodiagnostic composition comprising a combination of two or more substantially pure polypeptides, of which at least one or more comprises at least one amino acid sequence selected from
- (a) Rv3354 (SEQ ID NO. 148);
- (b) an immunogenic portion of the sequence in (a);
- and
- (c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic.
A composition comprising a combination of two or more substantially pure polypeptides, of which one or more comprises one or more amino acid sequence selected from the group consisting of:
- a) Rv3354 (SEQ ID NO. 148);
- b) an immunogenic portion of the sequence in (a);
- and
- c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic;
- and of which one or more comprises one or more amino acid sequences selected from the group consisting of:
- d) Rv0652, Rv2462c, Rv1984c, Rv2185c, Rv1636, Rv3451, Rv3872, Rv3354 and Rv2623;
- e) an immunogenic portion of any one of the sequences in (d);
- and
- f) an amino acid analogue having at least 70% sequence identity to any one of the sequences in (d) or (e) and at the same time being immunogenic.
Dependencies are inferred from the claim text.